Summary

The global contraceptive market has demonstrated significant growth, with an expected compound annual growth rate (CAGR) of 5.5% between 2019 and 2027, potentially reaching $30.15 billion by 2027. This expansion is attributed to factors such as demographic growth, increased government initiatives for awareness about unwanted pregnancies and Sexually Transmitted Infections (STIs), as well as changing lifestyles that delay childbearing. The French market follows a similar trend, driven by public awareness of contraception methods and STIs, coupled with investments by sector players in innovative products. Despite the "pill crisis" in 2012-2013 leading to decreased use of 3rd and 4th generation pills, the pill remains the most used contraceptive method in France. However, the market has seen shifts with increased adoption rates for IUDs and condoms post-crisis. France stands out in Europe for having relatively easy access to contraception, with a score of 90.1% for contraceptive accessibility in 2020. Major players in the global market include Allergan Plc, Bayer AG, and Merck.

Market Analysis: Shifts and Preferences in French Contraceptive Use

The French contraception market, reflecting both global trends and localized preferences, is continuing its growth trajectory, with a notable shift in the methods employed by French women to manage fertility and sexual health. A variety of contraceptive methods are in use, with hormonal pills, intrauterine devices (IUDs), and condoms being the most prevalent. As of 2018, around a third of women in France opt for contraceptive pills, while a quarter utilizes IUDs and about 16% prefer condoms. Implants and combined pill and condom usage each account for 5% of the methods chosen. Interestingly, the market witnessed a so-called "pill crisis" between 2012 and 2013, with significant public and regulatory scrutiny focused on 3rd and 4th generation contraceptive pills due to their associated health risks. This controversy led to a decline in pill usage from around 41% in 2010 to 32% in 2018, with no significant rise in women forgoing contraception altogether. Instead, there was a notable increase in the adoption of IUDs and condoms, suggesting a shift towards perceived safer and more convenient contraceptive options.

The French contraception market was valued at roughly between 330 and 335 million euros in 2016, and with an anticipated compounded annual growth rate (CAGR) of approximately 8.07%, it can be estimated to have approached 420 million euros in 2019. This growth is attributed to a heightened awareness of contraceptive methods and sexual health, continued innovation in the sector, and government initiatives promoting access and responsible family planning.

Globally, the market is even more dynamic, with a value of roughly between 22 and 23 billion US dollars in 2019, and an expected increase of about 23.3% in labor force participation over a five-year period since 2014. With an estimated CAGR of 5.5% from 2019 to 2027, worldwide contraceptive market revenues are projected to achieve around 30 billion US dollars by 2027. Factors such as demographic growth, changes in lifestyle, and increased educational and career opportunities for women have contributed to this uptrend. The global preference for contraceptive methods varies, with female sterilization, male condoms, and IUDs being the most common choices. In France, contraceptive usage preferences shift with age: women between 15 to 34 years favor the pill, while those aged 35 to 49 prefer IUDs.

Key Contraceptive Market Players: A Snapshot of Industry Leaders

In the dynamic landscape of contraceptive solutions, several key players stand out for their innovation, product offerings, and specialization in various segments of the market.

**Bayer AG**: Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. In the contraceptive market, Bayer has positioned itself as a specialist in the 3rd and 4th generation of contraceptive pills with popular products like Mélodia, Mélane, and Jasmine. They are also known for their intrauterine devices (IUDs) and had an impactful presence in the emergency contraception segment with the product EllaOne.

**Reckitt Benckiser Group (Durex)**: Reckitt Benckiser's Durex brand is a household name in sexual health, famously dominating the condom segment. With an impressive market share, Durex has created a wide range of condoms and is recognized for prioritizing safety, comfort, and pleasure.

**LifeStyles Healthcare (Manix, Skyn)**: Known for their Manix and Skyn brands, LifeStyles Healthcare has carved out significant market share in the sexual well-being and condom market. Their products are often hailed for innovative designs and materials, like the non-latex Skyn range that offers a natural feel.

**MSD France (Merck)**: With a broad portfolio that includes various healthcare products, MSD France is notable in the contraceptive market for its pill and emergency contraception options. They market an array of contraceptives under different brand names while promoting women's sexual health and well-being.

**Effik**: An Italy-based company that has made its mark in the French contraceptive market, mainly in oral contraceptives. Effik has a variety of generic alternatives to more well-known brands, making contraception more accessible and affordable to a broader audience.

**7 Med Industrie and CCD**: These French companies have established a strong foothold mainly in the intrauterine device (IUD) segment. They focus on offering effective and long-lasting contraceptive solutions through their IUDs, which are highly regarded for safety and efficacy.

**HRA Pharma**: Another leading company in the emergency contraception sector, HRA Pharma is the creator of the well-known Norlevo morning-after pill. Their products are often at the forefront of over-the-counter emergency contraceptive solutions and are known for their ease of use and accessibility.

**Theramex**: Is a dedicated women's healthcare company.

Get all the information you need
to understand this market

Detailed content

Inforamtion

  • Number of pages : 30 pages
  • Format : Digital and PDF versions
  • Last update : 27/05/2021
Update Details

Summary and extracts

1 Market overview

1.1 Definition and scope of the study

Contraception refers to all the methods used by men or women in order to make sexual intercourse infertile .

While the contraceptive pill remains the primary contraceptive method in France, there are many other means of contraception, of local or general action and of varying effectiveness and constraints :

  • Locally acting methods (avoids pregnancy at the time of intercourse): male or female condom, spermicide, diaphragm, cervical cap
  • Hormonal methods hormonally active substances of the estrogen or progestin type (pill, implant, injection, vaginal ring, patch, hormonal intrauterine device)
  • Surgical methods definitive methods by laparoscopic or hysteroscopic route in women and by scrotal route in men.
  • Natural Methods Methods that do not use external elements to regulate fertility (observation of the woman's menstrual cycle, Ogino method, calendar method, withdrawal method, etc.).
  • Male Methods Thermal male contraception method by  artificial cryptorchidism, the male pill
  • After a report emergency contraception (morning-after pill, two-day pill and copper intrauterine device).

The global contraceptive market was worth 22.49 billion in 2019 The number of employees is expected to increase by 23.3% in 5 years, compared to 2014. This turnover is expected to grow at a CAGR (compound annual growth rate) of 5.5% between 2019 and 2027. This upward trend in sales is mainly due to demographic growth, rising standards of development and living standards, the generalisation of studies and the increasing place of women in the labour market, which is accompanied by a mutiplication of maternity deferrals

The french market of contraception is also progressing. This growth is mainly driven by the growing awareness of the French population to contraceptive methods and sexually transmitted infections (STIs), the player investments of the sector to develop innovative products and government initiatives supporting improved access to contraception and information on contraceptive solutions and Family Planning.

In France, the pill is still the first method used despite the "pill crisis" at the end of 2012. The intrauterine system (IUD or IUD) and the condom are used by respectively 25% and 16% french women.

 

List of charts

  • Répartition des méthodes de contraception utilisées
  • Évolution des méthodes de contraception utilisées
  • Raisons d'arrêt de la pilule
  • Marché français des dispositifs contraceptifs
  • Prévisions de croissance sur le marché mondial de la contraception
Show more Hide

All our studies are available online in PDF format

Take a look at an example of our research on another market!

Do you have a question about this study?   +44 238 097 0676

Latest news

Companies quoted in this study

This study contains a complete overview of the companies in the market, with the latest figures and news for each company. :

Laboratoires Majorelle
Bayer France
MSD France
Effik France
Reckitt Bencksider France
LifeStyles Europe
Laboratoire 7 Med
Laboratoire CCD

Choosing this study means :

Access to more than 35 hours of work

Our studies are the result of over 35 hours of research and analysis. Using our studies allows you to devote more time and added value to your projects.

Benefit from 6 years' experience and over 1,500 industry reports already produced

Our expertise enables us to produce comprehensive studies in all sectors, including niche and emerging markets.

Our know-how and methodology enable us to produce reports that offer unique value for money.

Access to several thousand articles and paid-for data

Businesscoot has access to all the paid economic press as well as exclusive databases to carry out its market research (over 30,000 articles and private sources).

To enhance our research, our analysts also use web indicators (semrush, trends, etc.) to identify market trends and company strategies. (Consult our paying sources)

Guaranteed support after your purchase

A team dedicated to after-sales service, to guarantee you a high level of satisfaction. +44 238 097 0676

A digital format designed for our users

Not only do you have access to a PDF, but also to a digital version designed for our customers. This version gives you access to sources, data in Excel format and graphics. The content of the study can therefore be easily retrieved and adapted for your specific needs.

Our offers :

the contraceptive market | France

89 €
  • What are the figures on the size and growth of the market?
  • What is driving the growth of the market and its evolution?
  • What is the positioning of companies in the value chain?
  • Data from several dozen databases

Pack 5 études (-15%) France

75.6 € / study
378 € instead of 445 € -15%
  • 5 études au prix de 75,6€HT par étude à choisir parmi nos 800 titres sur le catalogue France pendant 12 mois
  • Conservez -15% sur les études supplémentaires achetées
  • Choisissez le remboursement des crédits non consommés au terme des 12 mois (durée du pack)

Consultez les conditions du pack et de remboursement des crédits non consommés.

Updates

Our customer references

They have consulted our studies Discover the opinions (+500)

Malcolm Vincent
Linkedin logo

Malcolm Vincent

Astoria Finance

Gregoire de Castelnau
Linkedin logo

Gregoire de Castelnau

Stags Participations

Timothé Huignard
Linkedin logo

Timothé Huignard

PWC

Paul-Alexis Kebabtchieff
Linkedin logo

Paul-Alexis Kebabtchieff

BCG

Aymeric Granet
Linkedin logo

Aymeric Granet

Publicis Consultant

interviews & case studies All interviews and case studies (45)

La pépite Interview

BFM Business

Paul-Alexis Kebabtchieff

Boston Consulting Group

Marie Guibart

Kea Partners

Elaine, Durand

Crédit Agricole, Information & Veille

Philippe Dilasser

Initiative & Finance

Anne Baudry

Metro

Amaury Wernert

Kroll (Duff & Phelps)

Smart Leaders Interview

B-Smart

Do you have a question ?
Our team is at your disposal at   +44 238 097 0676